Hemophilia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Hemophilia. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Hemophilia receives a directional score of 60/100, combining unmet need (65/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.

The reproducible record is Patsnap disease ID 2f7d97069f6945428cf65dd333b4e13d. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Population-Based Epidemiology of Heart Failure in a Low-Income Country: The Haiti Cardiovascular Disease Cohort

that the prevalence of HF may be dramatically higher, with numerous studies reporting HF among the most common causes of admission.10,11 Recently, the GBD study (Global Burden of Disease) estimation of HF prevalence in Haiti was 0.68%, which is approximately one-fifth our finding of 3.2%.1 The same study esti- mated HF prevalence across all low-income countries to be ≈0.77%, again highlighting a possible discordance between modeling studies, where locally derived model inputs are sparse, and population-based estimates. Sec- ond, the prevalence of HF in the United States ranges from 0.96% according to the GBD to 2.2% as reported in the most recent National Health and Nutrition Exami- nation Survey population-based data.1,34 Both are dra- matically lower than the 3.2% reported herein. Of note, Black patients have the highest prevalence of HF in the United States among all races, with estimates of 3.5% in 2016, which is more similar to our estimates.5 A simi- lar, and high, prevalence of HF among this Black Hai- tian cohort and Black Americans underscores a known cardiovascular health disparity and raises opportunities for further investigation of individual-, neighborhood-, and environmental-level influences contributing to the disparity gap.35 Taken together, these population-based data com- bined with global estimates and hospital-based stud- ies indicate that HF prevalence may be dramatically higher than previously reported, and HF may repre- sent an impending crisis in already fragile healthcare systems in these under-resourced settings most sub- ject to diagnostic, econo

Review source

Epidemiology evidence 2: Epidemiology of Heart Failure: A Contemporary Perspective Epidemiology of Heart Failure

The prevalence estimate in the US can be informally compared with the estimate of an American Heart Association forecasting study published in 2013.45 This study forecasted that the number of persons liv- ing with HF in 2020 in the United States would be 6 859 623, ≈2.1% of the population. Hence, the preva- lence of HF increased slightly less than anticipated, which is consistent with the aforementioned reports of declining incidence and stable mortality. However, HF is far more prevalent in older age groups, reaching 4.3% among persons aged 65 to 70 years old in 2012 and projected to increase steadily through year 2030 when the prevalence of HF could reach 8.5%.46 As a result, HF is often integrated into geriatric cardiovascu- lar syndromes with their inherent burden of multimorbid- ity and frailty, which considerably amplifies the personal and societal impact of the disease.46 Black persons with HF, particularly women, experience a disproportionately large excess prevalence of disability.46 Finally, estimates of the prevalence of overt HF not unexpectedly underestimate the true prevalence of HF as it relies on cases coming to medical atten- tion. The prevalence of HF as assessed by system- atic echocardiographic screening is substantially higher, even reaching 11.8% in a meta-analysis which, however, underscored the heterogeneity of methods across studies.47 HOSPITALIZATIONS AND READMISSIONS

Review source

Epidemiology evidence 3: Time and space co-ordinates of Hodgkin\\\'s lymphoma in Sardinia, Italy Time and space co-ordinates of Hodgkin’s lymphoma in Sardinia, Italy ☆

Results: The age- and sex-standardized (world population) incidence rate of HL was 2.6 per 100,000 (95% CI, 2.5–2.8). Over the study period, HL incidence increased linearly in both sexes and among those aged ≤ 44 years but not above that age . Cases clustered among young women in a central-western area covering four bordering administrative units (13 cases vs. 5.7 expected, P = 0.002). The posterior probability of excess HL cases aged ≤ 44 years was elevated only in a commune in the suburban area of the region’s capital. Cases aged ≥ 45 years were uniformly spread over the region. Among the risk factors we explored, urban residence was associated with an elevated and goat farming with a decreased risk of HL occurrence. We did not observe a link with socio- economic deprivation, environmental exposures, or multiple sclerosis. The geographic spread of COVID-19 was also unrelated to past HL incidence. Conclusions: Our results prompt further in-depth investigation into the previously undetected cluster and the nature of the observed associations. 1. Introduction

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Hemophilia, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Hemophilia thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 1327 registered studies.

• ChiCTR2600129829 — Construction and application of perioperative exercise program for total knee arthroplasty in hemophilia patients; Not yet recruiting; Not Applicable; sponsor Zhejiang Chinese Medicine Hospital; enrollment 8.
• NCT07736976 — Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers; Not yet recruiting; Not Applicable; sponsor Bahcesehir University; enrollment 58.
• CTR20262743 — 评价SV003注射液在伴或不伴抑制物的血友病A患者中用于规律替代治疗和/或预防治疗的有效性、安全性和药代动力学特征的多剂量、多中心Ⅱ期临床试验; 进行中 （尚未招募）; Phase 2; sponsor Shao Xing Xun Yao Pan Tuo Sheng Wu Yi Yao Ke Ji You Xian Gong Si, Shanghai Xunyao Biotechnology Co., Ltd.; enrollment Target enrollment: 国内: 56  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 6 directly matched 2023–2026 transactions.

• Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec (2024-12-30). Review stage, rights, territory, milestones and economics before using it as a comparable.
• 本导基因与上药睿尔达成下一代慢病毒载体技术授权合作 (2024-08-06). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases (2024-06-26). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate C5 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Hemophilia merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Hemophilia is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.